(Q36144411)

12 August 2017

1 reference

title

Pleiotropic renal actions of erythropoietin (English)

1 reference

12 August 2017

1 reference

1 reference

Prabal K Chatterjee

1

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

365

1 reference

12 August 2017

issue

9474

1 reference

12 August 2017

page(s)

1890-1892

1 reference

Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

Recombinant human erythropoietin stimulates angiogenesis and healing of ischemic skin wounds

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

EPO and alpha-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

Erythropoietin protects against ischaemic acute renal injury

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

Human, rat, and mouse kidney cells express functional erythropoietin receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

r.hu-erythropoietin (EPO) treatment of pre-ESRD patients slows the rate of progression of renal decline

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

Use of erythropoietin before the initiation of dialysis and its impact on mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

Oxygen radicals in cardiovascular-renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

Proliferation and remodeling of the peritubular microcirculation after nephron reduction: association with the progression of renal lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

Erythropoietin therapy for acute stroke is both safe and beneficial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

1 reference

7 January 2021

Pattern of prepro-endothelin-1 expression revealed by reporter-gene activity in kidneys of erythropoietin-overexpressing mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

Breast cancer trial with erythropoietin terminated unexpectedly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

New erythropoietic proteins: rationale and clinical data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

Derivatives of erythropoietin that are tissue protective but not erythropoietic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2966622-6

7 January 2021

10.1016/S0140-6736(05)66622-6

Identifiers

DOI

1 reference

12 August 2017

1 reference